Form 4: Director Lon Cardon Exercises Mirum Pharmaceuticals RSUs

Mirum Pharmaceuticals Director Lon Cardon acquired 3,977 shares of common stock through the vesting of restricted stock units.

Summary

• Director Lon Cardon acquired 3,977 shares of Mirum Pharmaceuticals (MIRM) common stock.
• The acquisition resulted from the vesting of restricted stock units (RSUs) on May 29, 2026.
• Following the transaction, the reporting person holds a total of 9,680 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the standard vesting of previously granted equity compensation to a director.

Positives

• The transaction reflects the vesting of equity compensation, aligning the director's interests with long-term shareholder value.

Negatives

• None identified.

Risks

• Standard market risks associated with holding equity in a biotechnology company.

Future Outlook

Not applicable as this is a routine disclosure of equity compensation vesting.

Industry Context

StockSavvy.ai notes that routine RSU vesting for directors is a standard corporate governance practice in the biotechnology sector, typically indicating the fulfillment of service-based equity awards rather than a change in market sentiment.

Comparison to Industry Standards

• The transaction is consistent with standard executive and director compensation structures in the mid-cap biotech industry.
• The reporting of RSU vesting on Form 4 complies with SEC Section 16(a) disclosure requirements.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• No future actions mentioned.

Key Dates

Keywords

MIRM, Mirum Pharmaceuticals, Form 4, Insider Trading, Director, Equity Vesting